Jacobio Pharmaceuticals Group Co. Ltd. has announced that its Investigational New Drug $(IND.AU)$ application for the Phase I/II clinical trial of its BET inhibitor, JAB-8263, for the treatment of autoimmune diseases, has been accepted by the Center for Drug Evaluation $(CDE)$ in China. This marks a significant step in expanding the therapeutic applications of JAB-8263 beyond oncology, where it has previously demonstrated good tolerability in clinical trials for solid tumors and hematological malignancies. The review of the IND application is expected to be completed within 30 working days, bringing hope for new oral treatment options in a field predominantly dominated by intravenous monoclonal antibodies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.